{"id":"nebivolol-tablets","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Fatigue"},{"rate":"3-8","effect":"Dizziness"},{"rate":"2-5","effect":"Headache"},{"rate":"2-4","effect":"Bradycardia"},{"rate":"1-3","effect":"Hypotension"},{"rate":"1-2","effect":"Dyspnea"}]},"_chembl":{"chemblId":"CHEMBL434394","moleculeType":"Small molecule","molecularWeight":"405.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nebivolol blocks beta-1 adrenergic receptors on the heart, decreasing heart rate and contractility to lower blood pressure and reduce cardiac workload. Unlike non-selective beta-blockers, it has additional vasodilatory properties mediated through nitric oxide release in endothelial cells, providing additional cardiovascular benefits beyond traditional beta-blockade.","oneSentence":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while also promoting nitric oxide-mediated vasodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:44.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Angina pectoris"},{"name":"Post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07233499","phase":"PHASE2","title":"Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-01-01","conditions":"HER2-positive Breast Cancer","enrollment":56},{"nctId":"NCT06104423","phase":"PHASE4","title":"Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2023-10-02","conditions":"Hypertension","enrollment":266},{"nctId":"NCT05513937","phase":"PHASE4","title":"Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2022-05-12","conditions":"Hypertension","enrollment":301},{"nctId":"NCT06201611","phase":"PHASE2, PHASE3","title":"Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.","status":"RECRUITING","sponsor":"St. John's Research Institute","startDate":"2024-11-15","conditions":"Diabetic Neuropathy Peripheral","enrollment":120},{"nctId":"NCT05279807","phase":"PHASE4","title":"Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2021-10-15","conditions":"Hypertension","enrollment":277},{"nctId":"NCT05257148","phase":"PHASE4","title":"Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2021-05-26","conditions":"Hypertension","enrollment":283},{"nctId":"NCT06289881","phase":"PHASE1","title":"Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2025-02-04","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT06249802","phase":"PHASE4","title":"Beta-blockade in Unruptured Intracranial Aneurysm","status":"NOT_YET_RECRUITING","sponsor":"Jagiellonian University","startDate":"2025-01-01","conditions":"Intracranial Aneurysm","enrollment":100},{"nctId":"NCT06248099","phase":"PHASE1","title":"Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-07-09","conditions":"Healthy Subjects","enrollment":46},{"nctId":"NCT06035978","phase":"PHASE4","title":"Determination of Drug Levels for Pharmacotherapy of Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-03","conditions":"Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction","enrollment":100},{"nctId":"NCT04631536","phase":"PHASE3","title":"Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC","status":"UNKNOWN","sponsor":"Lebanese American University Medical Center","startDate":"2021-01-10","conditions":"Covid19","enrollment":42},{"nctId":"NCT04888728","phase":"PHASE1","title":"To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-06-30","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":24},{"nctId":"NCT02391337","phase":"PHASE4","title":"Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2016-12-20","conditions":"Permanent Atrial Fibrillation","enrollment":161},{"nctId":"NCT04845061","phase":"PHASE4","title":"Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-10-01","conditions":"Copd","enrollment":30},{"nctId":"NCT01522950","phase":"PHASE2","title":"A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-05","conditions":"Hypertension","enrollment":76},{"nctId":"NCT01595516","phase":"PHASE4","title":"Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)","status":"COMPLETED","sponsor":"University of Colorado, Boulder","startDate":"2012-02","conditions":"Prehypertension, Hypertension","enrollment":44},{"nctId":"NCT01395329","phase":"PHASE4","title":"Nebivolol and the Endothelin (ET)-1 System","status":"COMPLETED","sponsor":"University of Colorado, Boulder","startDate":"2011-05","conditions":"Prehypertension, Hypertension","enrollment":42},{"nctId":"NCT03517020","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-04","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT03517033","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT01679652","phase":"PHASE2","title":"The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Erling Bjerregaard Pedersen","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":25},{"nctId":"NCT01885988","phase":"PHASE4","title":"Nebivolol Effects on Endothelial Function and Erectile Function","status":"UNKNOWN","sponsor":"Martin M. Miner, MD","startDate":"2013-03","conditions":"Erectile Dysfunction","enrollment":70},{"nctId":"NCT01415505","phase":"PHASE3","title":"Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-08","conditions":"Hypertension","enrollment":812},{"nctId":"NCT01415531","phase":"PHASE4","title":"Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-08","conditions":"Hypertension","enrollment":641},{"nctId":"NCT00849810","phase":"NA","title":"Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate","status":"TERMINATED","sponsor":"University of Mississippi Medical Center","startDate":"2009-01","conditions":"Hypertension","enrollment":1},{"nctId":"NCT01218100","phase":"PHASE4","title":"Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-10","conditions":"Stage 2 Diastolic Hypertension","enrollment":664},{"nctId":"NCT01076140","phase":"NA","title":"Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab","status":"WITHDRAWN","sponsor":"University of Mississippi Medical Center","startDate":"2010-02","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00744237","phase":"PHASE4","title":"Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Hypertension, Type 2 Diabetes Mellitus","enrollment":231},{"nctId":"NCT00734630","phase":"PHASE4","title":"Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Hypertension","enrollment":491},{"nctId":"NCT00770861","phase":"PHASE4","title":"A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-09","conditions":"Hypertension","enrollment":277},{"nctId":"NCT01248338","phase":"PHASE4","title":"Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function","status":"COMPLETED","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2006-03","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00785512","phase":"PHASE4","title":"A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-11","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00924833","phase":"PHASE4","title":"Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2006-05","conditions":"Hypoxia, Altitude, Heart Failure","enrollment":27},{"nctId":"NCT00942487","phase":"PHASE3","title":"Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol","status":"COMPLETED","sponsor":"Berlin-Chemie Menarini","startDate":"2005-04","conditions":"Primary Arterial Hypertension","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"HYPERKALAEMIA"},{"count":1,"reaction":"MUSCLE SPASMS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Nebivolol Tablets","genericName":"Nebivolol Tablets","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while also promoting nitric oxide-mediated vasodilation. Used for Hypertension, Heart failure with reduced ejection fraction, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}